Profile
Dr. Jack Gauldie is a Director at Ontario Genomics Institute (Private Equity).
Dr. Gauldie has been a member of the OGI's Board of Directors since September 2011.
He was Professor and Chair of the Department of Pathology and Molecular Medicine for 15 years (1989-2005) at McMaster University.
He currently holds the title of Distinguished Emeritus University Professor.
Recognized internationally for his work in defining the molecular regulation of the acute phase inflammatory response, he is a world expert in the areas of cytokine biology and the molecular regulation of inflammation and immunity.
He is also the lead investigator for McMaster's Institute for Molecular Medicine and Health.
In addition to his responsibilities at McMaster, he is a Fellow of the Royal Society of Canada and the Royal College of Physicians in Edinburgh.
Dr. Gauldie earned his BSc from McMaster University and his PhD from University College London.
Former positions of Jack Gauldie
| Companies | Position | End |
|---|---|---|
| McMaster University | Corporate Officer/Principal | 2004-12-31 |
Defyrus, Inc.
 Defyrus, Inc. Pharmaceuticals: MajorHealth Technology Defyrus, Inc. develops drugs to fight infectious viral diseases. Its products include DEF201, Aderon, and Ebola-ZMAb. The company was founded by David F. Masotti in 2008 and is headquartered in Toronto, Canada. | Director/Board Member | - |
Training of Jack Gauldie
| McMaster University | Undergraduate Degree |
| University College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Defyrus, Inc.
Defyrus, Inc. Pharmaceuticals: MajorHealth Technology Defyrus, Inc. develops drugs to fight infectious viral diseases. Its products include DEF201, Aderon, and Ebola-ZMAb. The company was founded by David F. Masotti in 2008 and is headquartered in Toronto, Canada. | Health Technology |
- Stock Market
- Insiders
- Jack Gauldie
